A Prospective Observational Study to Evaluate the Effectiveness of Deucravacitinib in Patients With Moderate Plaque Psoriasis in Real-World Settings in China (ADMIRE)
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Observational
SUMMARY
The purpose of this study is to collect and evaluate real-world data on the effectiveness of deucravacitinib treatment in adults with moderate plaque psoriasis in China.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Participant aged 18 years or older
• Physician-reported (dermatologist) diagnosis of moderate plaque psoriasis with Body Surface Area ≥ 3% and \< 10%
• Participant newly initiated deucravacitinib according to the label
• Provided written informed consent to participate in the study
Locations
Other Locations
China
Dermatology Hospital of Southern Medical University
RECRUITING
Guangzhou
Contact Information
Primary
BMS Study Connect Contact Center www.BMSStudyConnect.com
Clinical.Trials@bms.com
855-907-3286
Backup
First line of the email MUST contain NCT # and Site #.
Time Frame
Start Date: 2025-01-20
Estimated Completion Date: 2026-08-31
Participants
Target number of participants: 150
Treatments
Participants treated with deucravacitinib
Adults with moderate plaque psoriasis who are newly initiating deucravacitinib according to the product label
Related Therapeutic Areas
Sponsors
Leads: Bristol-Myers Squibb